The WIN Symposium 2025, held on October 3-4, 2025, successfully concluded as an officially endorsed event by the American Society of Clinical Oncology – marking the 14th consecutive year of this prestigious recognition.
Presented as Track 1 of the Advancing Precision Medicine Conference (APM), the symposium, titled ‘Progress and Challenges in Precision Oncology,’ brought together leading experts from around the world to explore the evolving landscape of precision oncology. Discussions highlighted groundbreaking advances in molecular diagnostics and targeted therapies, as well as the ongoing challenges of translating scientific discoveries into meaningful clinical outcomes.
Curated by the WIN Consortium, the symposium was co-chaired by Wafik El-Deiry, MD, PhD, FACP, Chair of the WIN Consortium, and Razelle Kurzrock, MD, FACP, Chief Medical Officer of the Consortium. The event featured distinguished speakers in cancer research, diagnostics, and therapeutic innovation, offering a comprehensive view of how precision medicine continues to reshape oncology across tumor types and care settings.
Wafik El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared some key highlights from the WIN Symposium:
Michael Pishvaian at 2025 WIN Consortium
“Dr. Michael Pishvaian at Johns Hopkins Kimmel Cancer Center speaks at the 2025 WIN Consortium in cancer personalized medicine WIN Symposium with Advancing Precision Medicine about biomarker-guided Rx in pancreatic cancer, PDAC will be the 2nd leading cause of cancer-related deaths by 2030, NAPOLI-3, NALIRI FOX, 5-10% exceptional response in PDAC but most drivers have not been targetable.
Now >25% have actionable targets, access to targeted Rx allows extra year of survival, 17-25% have altered DDR in PDAC, 5-7% BRCA1/2, 40% who have germline BRCA1/2 mutation have no family history, POLO trial, disproportionate benefit from Rx with MSI-Hi, NTRK fusion, NRG1 fusion (zenocutizumab), Ret fusions (pralsetinib, selpercatinib), KRAS WT may benefit from anti-EGFR in PDAC, G12C (adagrasib, sotorasib), RMC-6236 Daraxonrasib OS 14.5 mo vs 6 mo in second line, zoldonrasib (G12Di).”
Delighted that the AACR President attended the 2025 WIN Consortium
“We are delighted that American Association for Cancer Research President Dr. Lillian Siu, University of Toronto, attended and spoke at the 2025 WIN Consortium in cancer personalized medicine.”
World-renowned precision oncology experts at WIN Consortium
“World-renowned precision oncology experts discuss cases at WIN Consortium in cancer personalized medicine International Molecular Tumor Board Live at 2025 WIN Symposium in collaboration with Advancing Precision Medicine. Dr. Razelle Kurzrock presented 1st case of GBM and I presented 2nd case with multiple different active tumors.”
Fantastic presentation by Dr. Lillian Siu
“Fantastic presentation by Dr. Lillian Siu, President, American Association for Cancer Research 2025-2026
Director, Phase I Clinical Trials Program, Co-Director, Robert and Maggie Bras and Family Drug Development Program, Clinical Lead, Tumor Immunotherapy Program, BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre, Professor of Medicine, University of Toronto.
Dr. Siu discussed the INSPIRE trial, which included 188 tumor biopsies, 13 published manuscripts to date, awarded grants and impact on trainees. She discussed ctDNA as a predictive biomarker in solid tumor patients with Pembrolizumab treatment, Natera Assay, methylation in plasma signatures of response, endogenous retrotransposable elements, tertiary lymphoid structures, and spatial transcriptomics in head and Neck cancer.”
Razelle Kurzrock receives the Precision Oncology Award
“Dr. Razelle Kurzrock receives the 2025 WIN Consortium in cancer personalized medicine Precision Oncology Award for outstanding contributions to advancing cancer care through Precision Oncology.”
Photos with Bill Kaelin and others
“Photos with 2019 Nobel Laureate, Professor at Dana-Farber Cancer Institute and Keynote Speaker Dr. Bill Kaelin, American Association for Cancer Research President-Elect 2025-2026 and Director of Clinical Research Mass General Hospital Cancer Center Dr. Keith Flaherty and Director of Segal Cancer Center, Jewish General Hospital, McGill University Dr. Gerald Batist at speaker dinner 2025 WIN Consortium in cancer personalized medicine WIN Symposium in Philadelphia.”
Pashtoon Kasi discussed precision therapy in GI cancer
“Dr. Pashtoon Kasi at City of Hope discussed precision therapy in GI cancer, young CRC is mostly rectal and left-sided, high Her2 in gall bladder cancer, that RAS testing on tissue often isn’t back in 2 weeks, advantages of liquid biopsy to pick up heterogeneity, fusions, resistance mechanisms, at 2025 WIN Consortium in cancer personalized medicine.”
Superb panel of pediatric oncology experts
“Superb panel of pediatric oncology experts at 2025 WIN Consortium in cancer personalized medicine WIN Symposium in collaboration with Advancing Precision Medicine.”
You can also find Part 1 of “Highlights from WIN Symposium by Wafik El-Deiry” on OncoDaily.